Benzinga | Jun 30, 2021 08:04AM EDT

Longeveron Announces Two Abstracts Accepted For Presentation At The Gerontological Society Of America 2021 Annual Scientific Meeting

Longeveron Inc. (NASDAQ:LGVN) ("Longeveron" or "Company"), a clinical stage biotechnology company developing cellular therapies for chronic, aging-related and life-threatening conditions, today announced that two abstracts for Lomecel-B, the Company's investigational cell therapy being developed to treat aging-related life-threatening conditions, have been accepted for poster presentation at the Gerontological Society of America (GSA) 2021 Annual Scientific Meeting, being held November 10-14, 2021 in Phoenix, AZ. The full abstracts, including the dates and times of presentations, will be provided closer to the meeting once the GSA has provided these details to Longeveron. The titles of the presentations are as follows:



Title: A Phase 2b Clinical Trial Assessing Lomecel-B Infusion in Individuals with Aging Frailty: Study Design and Rationale.

Abstract ID: 1027576

Title: A Phase 1 Trial Assessing Lomecel-B Infusion in Individuals with Alzheimer's Disease: Study Design and Rationale

Abstract ID: 1028352

Additional meeting information can be found on the GSA Annual Scientific Meeting website at www.gsa2021.org. Once published, the presented posters will also be available under "Events & Presentations" in the Investors section of the Company's website at investors.longeveron.com.